Adipokines and their relation to endothelial dysfunction in patients with chronic kidney disease

Journal of Clinical and Diagnostic Research

Volumn 10, Issue 1, 2016, Pages BC04-BC08

  Ambarkar, Madhusudan ^a   Pemmaraju, Srinivasarao V L N ^a   Gouroju, Sivakrishna ^a   Manohar, Suchitra M ^a   Bitla, Aparna R ^a   Yajamanam, Naresh ^a   Vishnubhotla, Sivakumar ^a  

^a SRI VENKATESWARA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Adiponectin; Cardiovascular disease; Inflammation; Interleukin; Leptin; Tumour necrosis factor

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; C REACTIVE PROTEIN; CREATININE; INTERLEUKIN 10; INTERLEUKIN 6; LEPTIN; NITROUS OXIDE; TUMOR NECROSIS FACTOR ALPHA; UREA;

ADULT; ARTICLE; AUTOANALYZER; BLOOD ANALYSIS; CHEMICAL REACTION; CHRONIC KIDNEY DISEASE; COMORBIDITY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DISEASE ASSOCIATION; END STAGE RENAL DISEASE; ENDOTHELIAL DYSFUNCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL PHENOMENA; MIDDLE AGED; TURBIDIMETRY; ULTRAVIOLET SPECTROPHOTOMETRY;

EID: 84953299096     PISSN: 2249782X     EISSN: 0973709X     Source Type: Journal    
DOI: 10.7860/JCDR/2016/15867.7060     Document Type: Article

References (34)

1. Ritz E. Cardiovascular disease in patients with chronic kidney disease-An update. Hipertensriesgovas. 2010;27:75-79.
2. Suliman ME, Stenvinkel P. Contribution of inflammation to vascular disease in chronic kidney disease. Saudi J Kidney Dis Transplant. 2008;19(3):329-45.
3. Malyszko J. Mechanism of endothelial dysfunction in chronic kidney disease. Clin Chim Act. 2010;41:1412-20.
4. Axelsson J, Stenvinkel P. The emerging biology of adipose tissue in chronic kidney disease: from fat to facts. Nephrol Dial Transplant. 2008;2:3041-46.
5. Chudek J, Wiecek A. Adipose tissue, inflammation and endothelial dysfunction. Pharmacol Rep. 2006;58:S81-88.
6. Kaisar OM, Johnson DW, Prins JB, Isbel N. The role of novel biomarkers of cardiovascular disease in chronicKidney disease: focus on adiponectin and leptin. Curr Cardiol Rev.2008;4:287-92.
7. Stenvinkel P, Ketteler M, Johnson RJ, Lindholm B, Pecoits-Filho R, Riella M. IL-10, IL-6, and TNF-α: Central factors in the altered cytokine network of uraemia-The good, the bad, and the ugly. Kidney Int. 2005;67:1216-33.
8. Zoccali C. Endothelial dysfunction in CKD: a new player in town? Nephrol Dial Transplant. 2008;23:783-85.
9. Ruster C, Wolf G. Adipokines promote chronic kidney disease. Nephrol Dial Transplant. 2013;28(Suppl4):8-14.
10. Kir HM, Eraldemir C, Dervisoglu E, Caglayan C, Kalender B. Effects of chronic kidney disease and type of dialysis on serum levels of adiponectin, TNF-alpha and high sensitive C-reactive protein. Clin Lab. 2012;58(5-6):495-500.
11. Dounousi E, Koliousi E, Papagianni A, Ioannou K, Zikou X, Katopodis K, et al. Mononuclear leukocyte apoptosis and inflammatory markers in patients with chronic kidney disease. Am J Nephrol. 2012;36(6):531-36.
12. Lemos MM, Jancikic AD, Sanches FM, Christofalo DM, Ajzen SA, Carvalho AB, et al. Intima-media thickness is associated with inflammation and traditional cardiovascular risk factors in non-dialysis-dependent patients with chronic kidney disease. Nephron Clin Pract. 2010;115(3):189-94.
13. Yeo ES, Hwang JY, Park JE, Choi YJ, Huh KB, Kim WY. Tumour necrosis factor and C-reactive protein are positively associated with the risk of chronic kidney disease in patients with type 2 diabetes. Yonsei Med J. 2010;51(4):519-25.
14. Cortas NK, Wakid NW. Determination of inorganic nitrate in serum and urine by kinetic cadmium reduction method. Clin chem.1990;36(8):1440-43.
15. Zoccali C, Mallamaci F. Adiponectin and renal disease progression: another epidemiologic conundrum? Kidney Int. 2007;71:1195-97.
16. Sedighi O, Abediankenari S. Relationship between plasma adiponectin level with inflammatory and metabolic markers in patients with chronic kidney disease. Nephro Urol. 2014;6(1):11743.
17. Chitalia N, Raja RB, Bhandara T, Agrawal P, Kaski JC, Jha V, et al. Serum adiponectin and cardiovascular risk in chronic kidney disease and kidney transplantation. J Nephrol. 2010;23(1):77-84.
18. Robinson K, Prins J, Venkatesh B. Clinical review: Adiponectin biology and its role in inflammation and critical illness. Crit Care. 2011;15:221.
19. de Oliveira RB, Liabeuf S, Okazaki H, Lenglet A, Desjardins L, Lemke HD, et al. The clinical impact of plasma leptin levels in a cohort of chronic kidney disease patients. Clin Kid J. 2013;6:63-70.
20. El-Mougi HM, El-Yazeed SA, Yousry ZA, Fattah AA. Serum leptin in patients with chronic renal failure on different modes of management. The Egy J off Hosp Med. 2006;25:610-19.
21. Mak RH, Cheung W, Cone RD, Marks DL. Leptin and inflammation associated cachexia in chronic kidney disease. Kidney Int. 2006;69:794-97.
22. Barreto DV, Barreto FC, Liabeuf S, Temmar M, Lemke HD, Tribouilloy C. Plasma interleukin-6 is independently associatedwith mortality in both haemodialysis and pre-dialysispatients with chronic kidney disease. Kidney Int. 2010;77:550-56.
23. Teplan V, Vyhnanek F, Gurlich R, Haluzik M, Racek J, Vyhnankova I. Increased proinflammatory cytokine production in adipose tissue of obese patients with chronic kidney disease. Wien Klin Wochenschr. 2010;122(15-16):466-73.
24. Spoto B, Leonardis D, Parlongo RM, Pizzini P, Pisano A, Cutrupi S, et al. Plasma cytokines, glomerular filtration rate and adipose tissue cytokines gene expression in chronic kidney disease patients. Nutr Metab Cardiovasc Dis. 2012;22(11):981-88.
25. Biswas S, Ghoshal PK, Mandal SC, Mandal N. Relation of Anti- to Pro-Inflammatory Cytokine Ratios with Acute Myocardial Infarction. Korean J Intern Med. 2010; 25:44-50.
26. Singh U, Devaraj S, Dasu MR, Ciobanu D, Reusch J, Jialal I. C-reactive protein decreases interleukin-10 secretion in activated human monocyte-derived macrophages via inhibition of cyclic AMP production. Arterioscler Thromb Vasc Biol. 2006;26(11):2469-75.
27. Nand N, Aggarwal HK, Yadav RK, Gupta A, Sharma M. Role of high-sensitivity C-reactive protein as a marker of inflammation in pre-dialysis patients of chronic renal failure. JIACM. 2009;10:18-22.
28. Fisman EZ, Tenenbaum A. The ubiquitous interleukin-6: a time for reappraisal. Cardiovasc Diabetol. 2010;9:62.
29. Schmidt RJ, Baylis C. Total nitric oxide production is low in patients with chronic renal disease. Kidney Int. 2000;58(3):1261-26.
30. Baylis C. Arginine and arginine analogs and nitric oxide production in chronic kidney disease. Nat Clin Pract Nephrol. 2006;2:209-20.
31. Sowjanya N, Bitla AR, Suchitra MM, Siva Kumar V, SrinivasaRao PVLN. Endothelial dysfunction in early stages of chronic kidney disease: a pilot study. J Clin Sci Res. 2012;1:109-10.
32. Baylis C. Nitric oxide deficiency in chronic kidney disease. Am J Physiol Renal Physiol. 2008;294:F1-F9.
33. Bautista LE. Inflammation, endothelial dysfunction, and the risk of high blood pressure: epidemiologic and biological evidence. J Hum Hypertens. 2003;17(4):223-30.
34. Zyga S, Hutchison CA, Stringer S, Gil APR, Christopoulou G, Giata P, et al. Inflammation and Endothelial Dysfunction in the Initiation and Propagation of Cardiovascular Disease in Patients with Chronic Kidney Disease. Br J Med & Med Res. 2014;4(13):2568-80.